Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Provectus Pharmaceuticals (PVCT)
OTHER OTC:PVCT
Holding PVCT?
Track your performance easily
PVCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.04 - $0.22
Previous Close$0.11
Volume308.35K
Average Volume (3M)236.94K
Market Cap
$47.79M
Enterprise Value$47.75M
Total Cash (Recent Filing)$187.46K
Total Debt (Recent Filing)$148.26K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
May 09, 2018EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding420,279,879
10 Day Avg. Volume394,917
30 Day Avg. Volume236,935
Standard Deviation0.22
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-11.38
Price to Sales (P/S)48.41
Price to Cash Flow (P/CF)-20.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue79.21
Enterprise Value/Gross Profit85.61
Enterprise Value/Ebitda-16.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Provectus Pharmaceuticals News
PremiumCompany Announcements
Provectus Pharmaceuticals to Reveal Key 2024 Updates
PremiumCompany Announcements
Provectus Pharmaceuticals Converts Directors’ Fees to Preferred Stock
PremiumCompany Announcements
Provectus Pharmaceuticals Shares Annual Progress Update
PremiumCompany Announcements
Provectus Pharmaceuticals Announces New Leadership and StrategyOwnership Overview
11.95% Insiders
0.05% Other Institutional Investors
88.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PVCT FAQ
What was Provectus Pharmaceuticals’s price range in the past 12 months?
Provectus Pharmaceuticals lowest stock price was $0.04 and its highest was $0.22 in the past 12 months.
What is Provectus Pharmaceuticals’s market cap?
Currently, no data Available
When is Provectus Pharmaceuticals’s upcoming earnings report date?
Provectus Pharmaceuticals’s upcoming earnings report date is May 09, 2018 which is 2392 days ago.
How were Provectus Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Provectus Pharmaceuticals overvalued?
According to Wall Street analysts Provectus Pharmaceuticals’s price is currently Overvalued.
Does Provectus Pharmaceuticals pay dividends?
Provectus Pharmaceuticals does not currently pay dividends.
What is Provectus Pharmaceuticals’s EPS estimate?
Provectus Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Provectus Pharmaceuticals have?
Provectus Pharmaceuticals has 420,279,880 shares outstanding.
What happened to Provectus Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Provectus Pharmaceuticals?
Currently, no hedge funds are holding shares in PVCT
---
Provectus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-52.54%
Trailing 12-Months
Company Description
Provectus Pharmaceuticals
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treats several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.
---
Technical Analysis
Advaxis
―
Northwest Biotherapeutics
―
Anavex Life Sciences
―
ImmunoCellular Therapeutics
―
---